MARKET

CMPX

CMPX

Compass Therapeutics Inc
NASDAQ
1.890
+0.080
+4.42%
After Hours: 1.850 -0.04 -2.14% 19:35 05/20 EDT
OPEN
1.800
PREV CLOSE
1.810
HIGH
1.909
LOW
1.780
VOLUME
3.81M
TURNOVER
--
52 WEEK HIGH
6.88
52 WEEK LOW
1.610
MARKET CAP
340.37M
P/E (TTM)
-4.5930
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CMPX last week (0511-0515)?
Weekly Report · 2d ago
Compass Therapeutics to present at H.C. Wainwright BioConnect investor conference
PUBT · 05/12 11:30
Compass Therapeutics to Participate in Upcoming May Investor Events
Barchart · 05/12 06:30
Weekly Report: what happened at CMPX last week (0504-0508)?
Weekly Report · 05/11 10:22
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Tenax Therapeutics (TENX) and Compass Therapeutics (CMPX)
TipRanks · 05/10 02:10
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Compass Therapeutics (CMPX) and Addus Homecare (ADUS)
TipRanks · 05/07 07:40
Analysts Are Bullish on These Healthcare Stocks: Tempus AI, Inc. Class A (TEM), Compass Therapeutics (CMPX)
TipRanks · 05/06 11:20
Guggenheim Remains a Buy on Compass Therapeutics (CMPX)
TipRanks · 05/06 11:19
More
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.

Webull offers Compass Therapeutics Inc. stock information, including NASDAQ: CMPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPX stock methods without spending real money on the virtual paper trading platform.